Here IL‐1B antagonism via IL‐1B targeting monoclonal antibody Canakinumab improved Beta‐cell function, glycaemia, and reduced high‐sensitivity C‐reactive protein (hsCRP) by 39% and cardiovascular events by 15%, although an increased risk of infection warrants caution for further exploration of this treatment modality.45, 46. Here, IL1B is linked to infection.